Research programme: estrogen receptor peptide - eXegenics

Drug Profile

Research programme: estrogen receptor peptide - eXegenics

Alternative Names: Estrogen receptor peptide research programme - eXegenics

Latest Information Update: 25 Aug 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California at Los Angeles
  • Developer eXegenics; University of California at Los Angeles
  • Class
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 25 Aug 2003 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
  • 01 Aug 2003 Suspended - Preclinical for Breast cancer in USA (unspecified route)
  • 09 Nov 2001 Cytoclonal Pharmaceutics is now called eXegenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top